HUE027443T2 - Stat3 útvonal gátlók újszerû csoportja és tumor-õssejt útvonal gátlók - Google Patents

Stat3 útvonal gátlók újszerû csoportja és tumor-õssejt útvonal gátlók Download PDF

Info

Publication number
HUE027443T2
HUE027443T2 HUE08830619A HUE08830619A HUE027443T2 HU E027443 T2 HUE027443 T2 HU E027443T2 HU E08830619 A HUE08830619 A HU E08830619A HU E08830619 A HUE08830619 A HU E08830619A HU E027443 T2 HUE027443 T2 HU E027443T2
Authority
HU
Hungary
Prior art keywords
cancer
stat3
cells
compound
tumor
Prior art date
Application number
HUE08830619A
Other languages
English (en)
Inventor
Chiang Jia Li
Zhiwei Jiang
Harry Rogoff
Youzhi Li
Jifeng Liu
Wei Li
Original Assignee
Boston Biomedical Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Boston Biomedical Inc filed Critical Boston Biomedical Inc
Publication of HUE027443T2 publication Critical patent/HUE027443T2/hu

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A61K31/343—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D307/92—Naphthofurans; Hydrogenated naphthofurans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/24—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/42—Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/12—Keratolytics, e.g. wart or anti-corn preparations
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/50—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
    • C07D333/74—Naphthothiophenes
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Pulmonology (AREA)
  • Dermatology (AREA)
  • Oncology (AREA)
  • Rheumatology (AREA)
  • Cardiology (AREA)
  • Hematology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Biophysics (AREA)
  • Inorganic Chemistry (AREA)
  • Vascular Medicine (AREA)
  • Psychiatry (AREA)
  • Communicable Diseases (AREA)
  • Urology & Nephrology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Transplantation (AREA)
  • Diabetes (AREA)
  • Pain & Pain Management (AREA)
  • Molecular Biology (AREA)

Claims (4)

  1. készítmény, amely a következőkbe! -áll: f| vegyidet a következő csoportból választva: 2-acetik7-k!ór-n3ftöl2i3-blfurán-4,9'd$en; |-acet!í7-toí--na^ £«eetlHMrfto[23~ bjfurán-mg.-díon, :Μ^^12.3^Ιΐ0^η·»4^^#: löszförsav mm4H#&&oxa~n$MM~ tetrahidra'nafto[23-b]furá«^ői)-vWi| észter és foszförsav l-|4j-3fe5(ö-3%493a-tetrablcirx>-nafto[2,3-b]furán->2-i{}-vÍnÍífeter-ditr\ettlészter és ennek egy gyógyászatiiag elfogadható sója vagy szóivá^ és fii) egy kötőanyag, hordozó vagy oldószer, tumor-dsséif gátiásápan való felhasználásra olyan rak kezelésének esetén, amelynek ismerten vannak tumor-őssejtjei Is aberrált Stat3 útyönsImktMíása, olyan betegeknél., akiknek erre szükségük van, .ahol a kötőanyag, hordozó vagy oldószer a következőket tartalmazza:: lipkl a következő csoportból választva: tozfoiipid, szintetikus foszfefidii-koítn, tefmészétés foszfatidii-kolin, szfingomielin, semmid, foszfatidÜ-etanolemin, fosrfaüdil-glicerin, foszfadósav, koleszterin, koleszterin-szulfát, valamint haptén és poíietüeg-glikol (PEG) által konjogát fpdek intravénás adagoláshoz; vagy viaszos anyag a következő csoporfbél választve:: hiono-, dl- vágy fn-'gllééridóló 8 PEi mono- és di-zslrsa vészterel, PEéhgei: konjugáít g-vItatni « is ©eldcire: orális: adagoláshoz;: vagy a kötőanyag, hordozó vagy oldószer formája a kővetkező csoportból választott: miceíiáris emulzió,: szüszpenzié és nanorészecskés szuszpeozsé, továbbá tartalmaz még humán albumint Intravénás adagoláshoz, óz 1. igénypont szerinti felhasználású készítmény, ahol a készítmény a tumor-őssejt önmegújulását gátolja;. Az i. Igénypont szerinti felhasználású készítmény,: áhoka készítmény megöli éi tomon-össesiaket. Az 1, igénypont szerinti; felhasználásó vegyöfet ahol a rák fajtája a; kővetkező: csopcríhöi választott: emlődaganat, feji és nyak! daganat, tüdőrák, petefészefedaganat, hasnyálmirigy-daganat, kolorektális ksrcmőma, prosztatarák, melanoma, szarkoma, májdagaoat agydaganatok, myeloma multiplex és leukémia. Az l, Igénypont szerinti: felhasználású készítmény,. ahol; a rák metásztatskos. kemoterápiára vagy radfeterápiára: nem reagáló vagy a kezdeti kezelés után visszaeső. Az 1. igénypont szerinti felhasználású készítmény, alpi a rák a; következő csoportból; választott;: májdapnaí. feji és nyak! daganat, hasnyátalrlgy-tíagángt,: gypmorrék. yssérál, m*Mm, pfeelóma multiplex, metasztatikus emiőőageoat, ieakémla, limfóma, hyeíőcsőrafe agydaganat, giiőrna, hugyhólyagrák, endometriáiis daganat pajzsmlógyrák, epevezeíék-daganat, csontrák. skémrák IrétirmMasltbmal epeboíysgrék, ihifölskíspga^si;, -vastagbéldaganai, komrektáiis ^lamat, ^liiíri|^rá%: öír-garSí daganat, emlőrák, tüdőrák, prosztatarák, pet.##«^|k, risébnyffcráfc, melanoma és bőrrák:. ^ &&igénypont sxeríníí ifelhasanálásu késkftmány, ahol a rak kolöíéktiks rák, & & 6. igénypont szerinti ftelhasknálású készítmény, ahol a tik gyomorrak.: A $, Igé rsy:pí>nt »ÉI fáiba sznáiásct ü^ltmé hy, ahol a rák; nyéiocsősá k.
  2. 10. Az 1-S. igénypont bármelyike szsrmíi félhasznáiásó készítmény; aboí » M$ziímé«y· orális adagolasó ás napi négyszeri adagolásnál\-mm gyakoribb CQ.ID).
  3. 31. Az 1--6. Igénypont bármelyike szerinti felhasználású készítmény, ahol a készítményt l-'big/ro2 és kérölbélul 50 SÖÖ mg/mM^l közötti dózisban alkalmazzék.
  4. 12. Az 3 igénypont bármelyiké szerinti feidesználésu shot a Ms?ftm#nyl íö mg/nv és kör bibéiül §0 0(50 ?r5gymí £P0f közötti dózisban alkalmazzuk, 13 Az x, sgéeyppnt szerinti feihssznáíásó készítmény, ahol a vegyuiei 2meetrina0af2f3-b)fu;rán-á3· dión.
HUE08830619A 2007-09-10 2008-09-10 Stat3 útvonal gátlók újszerû csoportja és tumor-õssejt útvonal gátlók HUE027443T2 (hu)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US97114407P 2007-09-10 2007-09-10
US1337207P 2007-12-13 2007-12-13

Publications (1)

Publication Number Publication Date
HUE027443T2 true HUE027443T2 (hu) 2016-10-28

Family

ID=40452461

Family Applications (3)

Application Number Title Priority Date Filing Date
HUE08830471A HUE027657T2 (hu) 2007-09-10 2008-09-10 Új STAT3 útvonal inhibitorok és rák-õssejt inhibitorok
HUE08830633A HUE029111T2 (hu) 2007-09-10 2008-09-10 Rák kezelését célzó új készítmények és módszerek
HUE08830619A HUE027443T2 (hu) 2007-09-10 2008-09-10 Stat3 útvonal gátlók újszerû csoportja és tumor-õssejt útvonal gátlók

Family Applications Before (2)

Application Number Title Priority Date Filing Date
HUE08830471A HUE027657T2 (hu) 2007-09-10 2008-09-10 Új STAT3 útvonal inhibitorok és rák-õssejt inhibitorok
HUE08830633A HUE029111T2 (hu) 2007-09-10 2008-09-10 Rák kezelését célzó új készítmények és módszerek

Country Status (15)

Country Link
US (12) US8877803B2 (hu)
EP (6) EP2190429B1 (hu)
JP (16) JP5688840B2 (hu)
CN (6) CN101854802B (hu)
CA (4) CA2736564A1 (hu)
CY (3) CY1117604T1 (hu)
DK (4) DK3050566T3 (hu)
ES (3) ES2584904T3 (hu)
HK (3) HK1148942A1 (hu)
HR (3) HRP20160430T1 (hu)
HU (3) HUE027657T2 (hu)
PL (4) PL3067054T3 (hu)
PT (2) PT2194987T (hu)
SI (3) SI2194987T1 (hu)
WO (3) WO2009036099A1 (hu)

Families Citing this family (130)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102886045A (zh) 2005-02-03 2013-01-23 综合医院公司 治疗吉非替尼耐药性癌症的方法
AR057854A1 (es) 2005-11-04 2007-12-19 Wyeth Corp Combinaciones antineoplasicas con inhibidor de mtor, herceptina y/o hki-272 (e)-n-{4-[3-cloro-4-(2-piridinilmetoxi) anilino]-3-ciano-7-etoxi-6-quinolinil}-4-(dimetilamino)-2-butenamida
WO2009036099A1 (en) * 2007-09-10 2009-03-19 Boston Biomedical, Inc. A novel group of stat3 pathway inhibitors and cancer stem cell pathway inhibitors
US8022216B2 (en) 2007-10-17 2011-09-20 Wyeth Llc Maleate salts of (E)-N-{4-[3-chloro-4-(2-pyridinylmethoxy)anilino]-3-cyano-7-ethoxy-6-quinolinyl}-4-(dimethylamino)-2-butenamide and crystalline forms thereof
WO2009062199A1 (en) * 2007-11-09 2009-05-14 Fox Chase Cancer Center EGFR/NEDD9/TGF-β LNTERACTOME AND METHODS OF USE THEREOF FOR THE IDENTIFICATION OF AGENTS HAVING EFFICACY IN THE TREATMENT OF HYPERPROLIFERATIVE DISORDERS
US20130331294A1 (en) 2007-11-09 2013-12-12 Fox Chase Cancer Center Egfr/nedd9/tgf-beta interactome and methods of use thereof for the identification of agents having efficacy in the treatment of hyperproliferative disorders
UY31800A (es) * 2008-05-05 2009-11-10 Smithkline Beckman Corp Metodo de tratamiento de cancer usando un inhibidor de cmet y axl y un inhibidor de erbb
EP2915532B1 (en) 2008-06-17 2016-10-19 Wyeth LLC Antineoplastic combinations containing hki-272 and vinorelbine
WO2010005807A2 (en) 2008-07-08 2010-01-14 Board Of Regents, The University Of Texas System Novel inhibitors of proliferation and activation of signal transducer and activator of transcription (stats)
JP5681108B2 (ja) 2008-08-04 2015-03-04 ワイス・エルエルシー ４−アニリノ−３−シアノキノリンとカペシタビンの抗新生物薬の組合せ
WO2010065444A1 (en) * 2008-12-01 2010-06-10 University Of Central Florida Research Foundation, Inc. Drug composition cytotoxic for pancreatic cancer cells
RU2011139363A (ru) 2009-04-06 2013-05-20 ВАЙЕТ ЭлЭлСи Схема лечения рака молочной железы с использованием нератиниба
CN101897979B (zh) * 2009-05-27 2012-08-22 上海市计划生育科学研究所 治疗前列腺疾病的靶向药物
US20130129675A1 (en) * 2009-12-04 2013-05-23 Board Of Regents, The University Of Texas System Interferon therapies in combination with blockade of stat3 activation
KR101778320B1 (ko) * 2009-12-28 2017-09-13 잇반샤단호우징 화루마바레프로제쿠토 시엥기코우 1,3,4-옥사디아졸-2-카르복사미드 화합물
US20110275577A1 (en) * 2010-01-08 2011-11-10 Moleculin, Llc Methods of treating dermatologic, gynecologic, and genital disorders with caffeic acid analogs
US9427429B2 (en) 2010-03-01 2016-08-30 Tau Therapeutics Llc Cancer diagnosis and imaging
AU2015218436B9 (en) * 2010-03-19 2017-03-09 Boston Biomedical, Inc. Novel Methods For Targeting Cancer Stem Cells
BR122021025776B1 (pt) 2010-03-19 2022-12-27 Boston Biomedical, Inc. Composição compreendendo compostos de naftofurano e uso da mesma para tratar câncer
RU2591823C2 (ru) 2010-03-19 2016-07-20 Бостон Байомедикал, Инк. Новые способы направленного воздействия на раковые стволовые клетки
CN107721958A (zh) * 2010-03-19 2018-02-23 北京强新生物科技有限公司 靶向癌症干细胞的新的化合物和组合物
WO2011130677A1 (en) * 2010-04-16 2011-10-20 University Of Pittsburgh - Of The Commonwealth System Of Higher Education Inhibitors of cancer stem cells
US20110301194A1 (en) * 2010-06-02 2011-12-08 Arqule, Inc. Method for Determining Treatment Efficacy
CN103153975B (zh) * 2010-08-24 2016-01-20 杭州益尔生物科技有限公司 用于疾病治疗的新型萘醌
US20130236473A1 (en) * 2010-09-16 2013-09-12 Osaka University Therapeutic agents and prophylactic agents for symptoms accompanying autoimmune diseases, inflammatory diseases, allergy diseases and organ transplants
JP2013543011A (ja) * 2010-11-22 2013-11-28 グラクソスミスクライン、インテレクチュアル、プロパティー、ナンバー２、リミテッド 癌の治療法
CN103260647A (zh) * 2010-11-30 2013-08-21 伦敦健康科学中心研究公司 用于治疗心脏病的egfr拮抗剂
WO2012078982A2 (en) * 2010-12-09 2012-06-14 The Ohio State University Xzh-5 inhibits constitutive and interleukin-6-induced stat3 phosphorylation in human hepatocellular carcinoma cells
CN103402993A (zh) * 2011-03-04 2013-11-20 舟山海中洲新生药业有限公司 用于疾病治疗的4，9-二羟基-萘并[2,3-b] 呋喃新型酯
KR20120130658A (ko) * 2011-05-23 2012-12-03 주식회사 파멥신 펩타이드가 융합된 이중표적항체 및 그 용도
WO2012170439A1 (en) * 2011-06-06 2012-12-13 The Ohio State University Methods for stabilizing hypoxia inducible factor-2 alpha as a method for treating cancer
AU2012309800B2 (en) * 2011-09-12 2017-10-05 Cavion, Inc. Antagonists of products of the Hs.459642 unigene cluster for the inhibition of proliferation, development or differentiation of stem cells including cancer stem cells
EP2776586B1 (en) * 2011-11-11 2018-03-07 Millennium Pharmaceuticals, Inc. Biomarkers of response to proteasome inhibitors
WO2013120229A1 (en) * 2012-02-17 2013-08-22 Zhoushan Haizhongzhou Xinsheng Pharmaceuticals Co., Ltd. METHOD FOR PREPARING AQUEOUS MANO PARTICLE SUSPENSIONS OF DERIVATIVES OF 4,9-DIHYDROXY-NAPHTHO[2,3-b]FURAN ALIPHATIC ACID ESTERS
US8940742B2 (en) 2012-04-10 2015-01-27 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
WO2013166618A1 (en) * 2012-05-08 2013-11-14 Zhoushan Haizhongzhou Xinsheng Pharmaceuticals Co., Ltd. PRODRUGS OF 4,9-DIHYDROXY-NAPHTHO[2,3-b]FURANS FOR CIRCUMVENTING CANCER MULTIDRUG RESISTANCE
WO2014004376A2 (en) 2012-06-26 2014-01-03 Del Mar Pharmaceuticals Methods for treating tyrosine-kinase-inhibitor-resistant malignancies in patients with genetic polymorphisms or ahi1 dysregulations or mutations employing dianhydrogalactitol, diacetyldianhydrogalactitol, dibromodulcitol, or analogs or derivatives thereof
CN103705926A (zh) * 2012-10-08 2014-04-09 贾力 预防原发性肿瘤在手术切除后再转移的药用组合物
DE102013003107A1 (de) 2013-02-25 2014-09-11 Thomas Rühl Naphthofurandione mit einer 1-Bromalkylgruppe oder einer 1-Hydroxyalkylgruppe in 2-Position und einer Alkylgruppe in 3-Position zum Furanring-Sauerstoff und Verfahren zu deren Herstellung
KR20160061911A (ko) 2013-04-08 2016-06-01 데니스 엠. 브라운 최적하 투여된 화학 화합물의 치료 효과
SG11201508358RA (en) * 2013-04-09 2015-11-27 Boston Biomedical Inc 2-acetylnaphtho[2,3-b]furan -4,9-dione for use on treating cancer
CA2910855C (en) 2013-04-29 2024-04-02 Ogd2 Pharma Targeting o-acetylated gd2 ganglioside as a new therapeutic and diagnostic strategy for cancer stem cells cancer
US10745489B2 (en) 2013-04-29 2020-08-18 Ogd2 Pharma Targeting o-acetylated gd2 ganglioside as a new therapeutic and diagnostic strategy for Cancer Stem Cells cancer
JP6466924B2 (ja) 2013-10-04 2019-02-06 インフィニティー ファーマシューティカルズ， インコーポレイテッド 複素環式化合物及びその使用
WO2015051241A1 (en) 2013-10-04 2015-04-09 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
CN106132412A (zh) * 2014-01-27 2016-11-16 北京强新生物科技有限公司 治疗癌症的新方法
WO2015120304A1 (en) * 2014-02-07 2015-08-13 Boston Biomedical, Inc. 3-substituted carbonyl-naphtho[2,3-b]furane derivative or pharmaceutically acceptable salt thereof
US11406707B2 (en) 2014-02-10 2022-08-09 H. Lee Moffitt Cancer Center And Research Institute, Inc. STAT3 phosphorylation during graft-versus-host disease
US9775844B2 (en) 2014-03-19 2017-10-03 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
EP3122884B1 (en) * 2014-03-26 2019-12-25 Tocagen Inc. A retroviral vector having immune-stimulating activity
WO2015164870A1 (en) 2014-04-25 2015-10-29 H. Lee Moffitt Cancer Center And Research Institute, Inc. Gamma-aa-peptide stat3/dna inhibitors and methods of use
WO2015171985A1 (en) * 2014-05-09 2015-11-12 The Brigham And Women's Hospital, Inc. Treatment of igg-immune complex-mediated organ damage
WO2015190489A1 (ja) 2014-06-09 2015-12-17 京都薬品工業株式会社 新規抗癌剤
US10869926B2 (en) * 2014-07-15 2020-12-22 The Johns Hopkins University Suppression of myeloid derived suppressor cells and immune checkpoint blockade
US9708348B2 (en) 2014-10-03 2017-07-18 Infinity Pharmaceuticals, Inc. Trisubstituted bicyclic heterocyclic compounds with kinase activities and uses thereof
KR20160066490A (ko) * 2014-12-02 2016-06-10 주식회사 씨앤드씨신약연구소 헤테로사이클 유도체 및 그의 용도
CN113501826A (zh) 2015-01-08 2021-10-15 美国政府健康及人类服务部 作为tdp2的抑制剂的呋喃并喹啉二酮
JP6630364B2 (ja) 2015-03-27 2020-01-15 ボストン バイオメディカル， インコーポレイテッド 水溶性プロドラッグ
CN104725480A (zh) * 2015-04-06 2015-06-24 苏州普罗达生物科技有限公司 一种信号传导及转录激活因子抑制多肽及其应用
CN104693280A (zh) * 2015-04-06 2015-06-10 苏州普罗达生物科技有限公司 信号传导及转录激活因子抑制多肽及其应用
CN104693279A (zh) * 2015-04-06 2015-06-10 苏州普罗达生物科技有限公司 关于信号传导及转录激活因子抑制多肽及其应用
EP3283071A1 (en) * 2015-04-17 2018-02-21 Boston Biomedical, Inc. Methods for treating cancer
EA201792287A1 (ru) * 2015-04-17 2018-03-30 Бостон Биомедикал, Инк. Способы лечения рака
MX2017013358A (es) * 2015-04-17 2018-08-01 Boston Biomedical Inc Métodos para tratar el cáncer.
US20180250261A1 (en) * 2015-04-27 2018-09-06 Boston Biomedical, Inc. Method for treating cancer with a stat3 pathway inhibitor and kinase inhibitor
BR112017024461B1 (pt) 2015-05-14 2023-04-04 NuCana plc Usos de nuc-1031 para o tratamento de câncer
US10881664B2 (en) * 2015-05-15 2021-01-05 Novartis Ag Methods for treating EGFR mutant cancers
MX2017015618A (es) 2015-06-03 2018-08-15 Boston Biomedical Inc Composiciones que comprenden un inhibidor de la autorrenovación y diferenciación de células madre cancerosas y un agente inmunoterapéutico para su uso en el tratamiento del cáncer.
US10329267B2 (en) 2015-07-17 2019-06-25 Sumitomo Dainippon Pharma Co., Ltd. Method for producing 2-acetyl-4H,9H-naphtho[2,3-b]furan-4,9-dione
WO2017013270A1 (en) 2015-07-23 2017-01-26 Universite De Strasbourg Use of leptin signaling inhibitor for protecting kidneys from patients having ciliopathy
WO2017023866A1 (en) * 2015-07-31 2017-02-09 Boston Biomedical, Inc. Method of targeting stat3 and other non-druggable proteins
CA2998469A1 (en) 2015-09-14 2017-03-23 Infinity Pharmaceuticals, Inc. Solid forms of isoquinolinones, and process of making, composition comprising, and methods of using the same
CA2994502C (en) 2015-10-05 2023-08-01 NuCana plc Combination therapy comprising nuc-1031 and carboplatin for cancer treatment
CA3010786A1 (en) * 2016-01-07 2017-07-13 Virginia Commonwealth University A method of modulating survival and stemness of cancer stem cells by mda-9/syntenin (sdcbp)
CN109069469A (zh) * 2016-01-20 2018-12-21 北京强新生物科技有限公司 治疗癌症的方法
CN109104862A (zh) * 2016-03-01 2018-12-28 中央研究院 4,9-二氧代-4,9-二氢萘并[2,3-b]呋喃-3-羧酰胺衍生物及其用于治疗增生性疾病与感染性疾病的用途
US11946927B2 (en) 2016-03-14 2024-04-02 Musidora Biotechnology Llc Process and system for identifying individuals having a high risk of inflammatory bowel disease and a method of treatment
US10295527B2 (en) 2016-03-14 2019-05-21 Bruce Yacyshyn Process and system for predicting responders and non-responders to mesalamine treatment of ulcerative colitis
WO2017161116A1 (en) 2016-03-17 2017-09-21 Infinity Pharmaceuticals, Inc. Isotopologues of isoquinolinone and quinazolinone compounds and uses thereof as pi3k kinase inhibitors
JP2017171640A (ja) * 2016-03-25 2017-09-28 学校法人兵庫医科大学 癌の治療システム
US10738023B2 (en) 2016-03-25 2020-08-11 Sumitomo Dainippon Pharma Co., Ltd. Method for producing 2-alkylcarbonylnaphtho[2,3-b]furan-4,9-dione-related substance, and said related substance
CN105906595A (zh) * 2016-04-23 2016-08-31 陈斌 丙酸倍氯米松的药物组合物及其在生物医药中的应用
CN105837541A (zh) * 2016-04-23 2016-08-10 何淑琼 磷酸苯丙哌林的药物组合物及其在生物医药中的应用
GB201609600D0 (en) 2016-06-01 2016-07-13 Nucuna Biomed Ltd Cancer treatments
US10919914B2 (en) 2016-06-08 2021-02-16 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
CA3029596A1 (en) 2016-06-28 2018-01-04 Boston Biomedical, Inc. Methods for treating cancer
CN106380456B (zh) * 2016-08-29 2019-03-26 中南大学 一种合成苯并呋喃萘醌衍生物的方法
WO2018098352A2 (en) 2016-11-22 2018-05-31 Jun Oishi Targeting kras induced immune checkpoint expression
WO2018096401A1 (en) 2016-11-22 2018-05-31 Hitoshi Ban New naphtho[2,3-b]furan derivatives
CA3045306A1 (en) 2016-11-29 2018-06-07 Boston Biomedical, Inc. Naphthofuran derivatives, preparation, and methods of use thereof
MX2019006326A (es) * 2016-11-30 2019-07-12 Tyme Inc Derivados de tirosina y composiciones que los comprenden.
WO2018133838A1 (zh) * 2017-01-22 2018-07-26 江苏恒瑞医药股份有限公司 Egfr/her2抑制剂联合嘧啶类抗代谢药物的用途
WO2018183908A1 (en) * 2017-03-31 2018-10-04 Dana-Farber Cancer Institute, Inc. Compositions and methods for treating ovarian tumors
JP2020520923A (ja) 2017-05-17 2020-07-16 ボストン バイオメディカル， インコーポレイテッド がんを処置するための方法
CA3066054A1 (en) * 2017-06-04 2018-12-13 Rappaport Family Institute For Research In The Medical Sciences Method of predicting personalized response to cancer therapy and kit therefor
EP3654841B1 (en) * 2017-07-20 2024-02-07 Board Of Supervisors Of Louisiana State University Targeted osmotic lysis of malignant cancer cells using pulsed magnetic field gradients
EP3686182A4 (en) 2017-09-22 2021-06-09 Sumitomo Dainippon Pharma Co., Ltd. CHEMICALLY ACTIVATED WATER-SOLUBLE PRODRUG
KR20240065190A (ko) * 2017-11-16 2024-05-14 티르노보 리미티드 암 치료용 irs/stat3 이중 조절제 및 항 pd-1/pd-l1 항체의 조합물
EP3501511A1 (en) * 2017-12-22 2019-06-26 Fundación Centro Nacional De Investigaciones Oncológicas Carlos III Means for preventing and treating brain metastasis
JP7336386B2 (ja) * 2017-12-28 2023-08-31 株式会社カネカ 多能性幹細胞凝集抑制剤
CN107973788B (zh) * 2018-01-09 2021-07-09 沈阳药科大学 Bbi608衍生物及其制备与用途
SG11202007979UA (en) * 2018-03-20 2020-09-29 Sumitomo Dainippon Pharma Co Ltd Dihydrochromene derivative
JP7411315B2 (ja) * 2018-04-19 2024-01-11 トゥヴァルディ セラピューティクス，インク． Ｓｔａｔ３阻害剤
WO2019232214A1 (en) 2018-05-31 2019-12-05 Boston Biomedical, Inc. Methods of using napabucasin
EP3854397A4 (en) * 2018-09-18 2022-07-13 Kabushiki Kaisha Yakult Honsha CANCER MULTIPLE THERAPY USING A QUINOLINE CARBOXAMIDE DERIVATIVE
MX2021004151A (es) * 2018-10-12 2021-09-08 1Globe Biomedical Co Ltd Nueva solución de combinación para el tratamiento contra cáncer refractario a la quimioterapia.
CN109846888A (zh) * 2018-10-31 2019-06-07 南京先进生物材料与过程装备研究院有限公司 一种紫杉醇和吲哚类stat3抑制剂联合用药物组合物
CN109288847A (zh) * 2018-10-31 2019-02-01 南京先进生物材料与过程装备研究院有限公司 一种紫杉醇和咔唑类stat抑制剂甲磺酸盐晶型p联合用药物组合物
CN109223758A (zh) * 2018-10-31 2019-01-18 南京先进生物材料与过程装备研究院有限公司 一种紫杉醇和芴类stat3抑制剂联合用药物组合物
CN109172563A (zh) * 2018-10-31 2019-01-11 南京先进生物材料与过程装备研究院有限公司 一种噻吨酮类紫杉醇和stat3抑制剂联合用药物组合物
CN109200044A (zh) * 2018-10-31 2019-01-15 南京先进生物材料与过程装备研究院有限公司 一种紫杉醇和二苯并[b,d]噻吩类STAT抑制剂酒石酸盐联合用药物组合物
CN109331004A (zh) * 2018-10-31 2019-02-15 南京先进生物材料与过程装备研究院有限公司 一种紫杉醇和二苯并[b,d]噻吩类STAT抑制剂甲磺酸盐A晶型联合用药物组合物
CN109966297A (zh) * 2018-10-31 2019-07-05 南京先进生物材料与过程装备研究院有限公司 一种紫杉醇和咔唑类stat抑制剂马来酸盐晶型i联合用药物组合物
CN109288845A (zh) * 2018-10-31 2019-02-01 南京先进生物材料与过程装备研究院有限公司 一种咔唑类stat抑制剂马来酸盐晶型ii联合用药物组合物及其制备方法
CN109200052A (zh) * 2018-10-31 2019-01-15 南京先进生物材料与过程装备研究院有限公司 一种紫杉醇和芴酮类stat3抑制剂联合用药物组合物
CN109288846A (zh) * 2018-10-31 2019-02-01 南京先进生物材料与过程装备研究院有限公司 一种紫杉醇和咔唑类stat3抑制剂晶型a联合用药物组合物
CN109364252B (zh) * 2018-11-21 2021-09-28 南京大学 抑制ifn-i至arg1诱导通路在制备抗肿瘤药物组合物中的应用
CA3136230A1 (en) * 2019-04-09 2020-10-15 Generos Biopharma Ltd. Pharmaceutical combination of pimozide and methotrexate and use thereof
US11564913B2 (en) * 2019-05-03 2023-01-31 Children's Hospital Medical Center Compositions and methods for treating cancer
CN110218198B (zh) * 2019-05-22 2022-06-28 广州中医药大学(广州中医药研究院) 一种萘醌并三氮唑核心骨架衍生物化合物及其制备方法和应用
WO2020251015A1 (ja) * 2019-06-14 2020-12-17 大日本住友製薬株式会社 ２－アルキルカルボニル［２，３－ｂ］フラン－４，９－ジオンの製造方法、及びその製造中間体
JP7287929B2 (ja) * 2019-09-25 2023-06-06 住友ファーマ株式会社 ジヒドロクロメン誘導体を含有する医薬
US20220401436A1 (en) * 2019-11-08 2022-12-22 INSERM (Institute National de la Santé et de la Recherche Médicale) Methods for the treatment of cancers that have acquired resistance to kinase inhibitors
KR20220131224A (ko) * 2019-11-20 2022-09-27 예일 유니버시티 허혈-재관류 손상 및/또는 폐 손상을 치료하기 위한 화합물, 조성물 및 방법
US20230013636A1 (en) * 2019-12-05 2023-01-19 Board Of Regents, The University Of Texas System Exosomes-based therapy for liver fibrosis and other diseases with fibrosis
WO2021185234A1 (zh) * 2020-03-16 2021-09-23 正大天晴药业集团股份有限公司 作为c-Met激酶抑制剂的化合物的联用药物组合物及其用途
US20230192601A1 (en) * 2020-05-11 2023-06-22 Purdue Research Foundation Scaled-up synthesis of lomustine under control flow conditions
WO2022022524A1 (en) * 2020-07-27 2022-02-03 Huazhong University Of Science & Technology Prevention and/or treatment of a disease associated with stat3
WO2022216930A1 (en) * 2021-04-08 2022-10-13 Virginia Commonwealth University Novel mda-9 antagonist with anti-metastatic potential
CN114591306B (zh) * 2022-03-03 2024-03-01 陕西中医药大学 一种1,2,4-三唑环的1,4萘醌类stat3抑制剂及其应用

Family Cites Families (84)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2472133A (en) * 1947-03-20 1949-06-07 Du Pont Thiophanthraquinone derivatives
SU1049490A1 (ru) 1982-05-18 1983-10-23 Ордена Трудового Красного Знамени Институт Химии Ан Мсср (3 @ ,9 @ ,9 @ )-6,6,9 @ -Триметилтранспергидронафто(2,1- @ )фуран,в качестве душистого компонента парфюмерной композиции
JPS616149A (ja) 1984-06-20 1986-01-11 Mitsubishi Electric Corp 無機絶縁体の製法
JPS63196576A (ja) * 1987-02-10 1988-08-15 Tetsuo Ikegawa フラルナフトキノン誘導体と制癌剤及びその製造方法
EP0309926A3 (de) 1987-09-29 1990-12-05 Siemens Aktiengesellschaft Verfahren zur Herstellung vollparametrisierbarer Schaltungen in integrierter Schaltkreistechnik
JPH01121284A (ja) 1987-11-06 1989-05-12 Eisai Co Ltd トコフェロール　ｎ，ｎ−ジアルキルアミノアルキルカルボン酸エステルの胆汁酸塩
EP0402192A1 (fr) 1989-05-31 1990-12-12 BODET, Jean Augustin Article en carton ou matière analogue et procédé de fabrication
JPH04139177A (ja) 1989-12-28 1992-05-13 Dainippon Ink & Chem Inc フラルベンゾキノン誘導体及びその製造方法並びに制癌剤
DE69131856T2 (de) * 1990-07-10 2000-06-15 Canon Kk Lichtempfindliches elektrophotographisches Element
JP2942015B2 (ja) * 1990-07-10 1999-08-30 キヤノン株式会社 電子写真感光体およびそれを用いた電子写真装置
TW252136B (hu) * 1992-10-08 1995-07-21 Ciba Geigy
JP3598168B2 (ja) 1996-03-18 2004-12-08 独立行政法人 科学技術振興機構 抗ウイルス剤
JPH1121284A (ja) 1997-06-30 1999-01-26 Kotobuki:Kk フラノナフトキノン誘導体及びこれを含有する医薬
JPH1165141A (ja) * 1997-08-11 1999-03-05 Canon Inc 電子写真感光体、該電子写真感光体を有するプロセスカ−トリッジ及び電子写真装置
US6174913B1 (en) 1998-06-05 2001-01-16 The University Of North Carolina At Chapel Hill Naphtho- and dihydrobenzo-thiophene derivatives as cytotoxic antitumor agents
EP1146869A2 (en) * 1999-01-27 2001-10-24 University Of South Florida Inhibition of stat3 signal transduction for human cancer therapy
DK1169021T3 (da) * 1999-04-01 2010-01-11 Hana Biosciences Inc Sammensætninger og fremgangsmåder til behandling af lymfom
US6482943B1 (en) * 1999-04-30 2002-11-19 Slil Biomedical Corporation Quinones as disease therapies
JP3961827B2 (ja) 1999-08-02 2007-08-22 エフ．ホフマン−ラ ロシュ アーゲー 新規な選択的レチノイドアゴニスト
JP2001097860A (ja) 1999-09-29 2001-04-10 Japan Science & Technology Corp 抗薬剤耐性菌剤と抗クラミジア剤
UA75055C2 (uk) 1999-11-30 2006-03-15 Пфайзер Продактс Інк. Похідні бензоімідазолу, що використовуються як антипроліферативний засіб, фармацевтична композиція на їх основі
KR20010100194A (ko) 2000-03-13 2001-11-14 박호군 여러 가지 물질의 가용화용 조성물과 제형 및 그들의제조방법
WO2002078617A2 (en) 2001-03-28 2002-10-10 University Of South Florida Materials and methods for treatment of cancer and identification of anti-cancer compounds
GB0117696D0 (en) 2001-07-20 2001-09-12 Bradford Particle Design Plc Particle information
AU2002357012A1 (en) * 2001-11-27 2003-06-10 Transform Pharmaceuticals, Inc. Oral pharmaceutical formulations comprising paclitaxel, derivatives and methods of administration thereof
CN1310652C (zh) 2001-11-29 2007-04-18 特拉科斯有限公司 用体外光提取法和/或凋亡细胞对被试者进行预治疗的方法
CA2478338A1 (en) * 2002-03-08 2003-09-18 Signal Pharmaceuticals, Inc. Combination therapy for treating, preventing or managing proliferative disorders and cancers
DK1344533T3 (da) * 2002-03-15 2007-01-08 Natimmune As Farmaceutiske præparater, der omfatter mannosebindende lectin
WO2004024145A1 (en) 2002-09-10 2004-03-25 Dabur Research Foundation Anti-cancer activity of carvedilol and its isomers
EP1551392A4 (en) 2002-09-17 2006-09-20 Arqule Inc NOVEL LAPACHO COMPOUNDS AND METHODS OF USE THEREOF
AR042052A1 (es) 2002-11-15 2005-06-08 Vertex Pharma Diaminotriazoles utiles como inhibidores de proteinquinasas
TWI323662B (en) 2002-11-15 2010-04-21 Telik Inc Combination cancer therapy with a gst-activated anticancer compound and another anticancer therapy
IS6633A (is) 2002-11-22 2004-05-23 Omega Farma Ehf. Samsetningar af fínasteríð töflum
AU2004256425A1 (en) * 2003-06-09 2005-01-20 The Regents Of The University Of Michigan Compositions and methods for treating and diagnosing cancer
US7566798B2 (en) 2003-08-13 2009-07-28 University Of South Florida Platinum complexes and methods of use
US20050049207A1 (en) 2003-09-03 2005-03-03 Kaufmann Doug A. Method of treating and preventing cancer
WO2005033048A2 (en) 2003-09-29 2005-04-14 The Johns Hopkins University Wnt pathway antagonists
PT1706133E (pt) 2003-12-02 2010-12-07 Cleveland Clinic Foundation Métodos para protecção contra radiação utilizando flagelina
KR101170655B1 (ko) * 2003-12-11 2012-08-03 더 보드 오브 리전츠 오브 더 유니버시티 오브 텍사스 시스템 세포 증식 질환 치료용 화합물
DE10359828A1 (de) * 2003-12-12 2005-07-28 Zoser B. Dr.Rer.Nat. Salama CHP-Gemcitabin- Kombinationsmittel und ihre Verwendung als Antitumorwirkstoffe, insbesondere Antimetastasierungswirkstoffe
EP1748772A2 (en) 2004-04-09 2007-02-07 University Of South Florida Combination therapies for cancer and proliferative angiopathies
JP2004224802A (ja) 2004-04-21 2004-08-12 Japan Science & Technology Agency 抗菌剤
EP1768977A2 (en) * 2004-07-02 2007-04-04 ICOS Corporation Compounds useful for inhibiting chk1
DE602005017283D1 (de) * 2004-08-18 2009-12-03 Astrazeneca Ab Ausgewählte kondensierte heterocyclen und deren anwendung
JP2008519036A (ja) * 2004-11-08 2008-06-05 バクスター・インターナショナル・インコーポレイテッド チューブリン阻害化合物のナノ粒子組成物
EP1885352A2 (en) * 2004-11-24 2008-02-13 Novartis AG Combinations comprising jak inhibitors and at least one of bcr-abl, flt-3, fak or raf kinase inhibitors
WO2006071812A2 (en) * 2004-12-23 2006-07-06 H. Lee Moffitt Cancer Center And Research Institute Platinum iv complex inhibitor
CA2599393A1 (en) * 2005-02-25 2006-08-31 The Regents Of The University Of Michigan Small molecule inhibitors of stat3 and the uses thereof
JP2006248978A (ja) * 2005-03-10 2006-09-21 Mebiopharm Co Ltd 新規なリポソーム製剤
JP2006290871A (ja) 2005-03-16 2006-10-26 Taheebo Japan Kk 抗癌性を示す化合物およびその中間体ならびにそれらの製造方法
US20060252073A1 (en) * 2005-04-18 2006-11-09 Regents Of The University Of Michigan Compositions and methods for the treatment of cancer
WO2006126505A1 (ja) 2005-05-26 2006-11-30 The University Of Tokyo Stat機能阻害剤およびその応用
US8133692B2 (en) * 2005-07-20 2012-03-13 University Of South Florida Methods of predicting responsiveness to chemotherapeutic agents and selecting treatments
BRPI0617364A2 (pt) 2005-10-13 2011-07-26 Orchid Res Lab Ltd compostos heterocÍclicos como inibidores de pstat3/il-6
UA96139C2 (uk) * 2005-11-08 2011-10-10 Дженентек, Інк. Антитіло до нейропіліну-1 (nrp1)
AR057579A1 (es) * 2005-11-23 2007-12-05 Merck & Co Inc Compuestos espirociclicos como inhibidores de histona de acetilasa (hdac)
JP2007145680A (ja) 2005-11-30 2007-06-14 Idemitsu Kosan Co Ltd 水素発生材料および水素発生方法
AU2006329681A1 (en) * 2005-12-24 2007-07-05 Biotica Technology Ltd. 21-deoxymacbecin analogues useful as antitumor agents
AU2007208494A1 (en) * 2006-01-12 2007-08-02 Merck Sharp & Dohme Corp. Fluorinated arylamide derivatives
CA2635797C (en) * 2006-02-09 2015-03-31 Macusight, Inc. Stable formulations, and methods of their preparation and use
WO2007100640A2 (en) * 2006-02-21 2007-09-07 The Regents Of The University Of Michigan Growth hormone receptor antagonist cancer treatment
WO2007095753A1 (en) * 2006-02-24 2007-08-30 Merck Frosst Canada Ltd. 2-(phenyl or heterocyclic) - 1h-phenanthro [9,10-d] imidazoles
RU2456265C2 (ru) * 2006-03-31 2012-07-20 Дзе Борд Оф Риджентс Оф Дзе Юниверсити Оф Техас Систем Биологически доступная для перорального применения кофейная кислота, относящаяся к противоопухолевым лекарственным средствам
US20070238770A1 (en) 2006-04-05 2007-10-11 Bristol-Myers Squibb Company Process for preparing novel crystalline forms of peliglitazar, novel stable forms produced therein and formulations
WO2008094321A2 (en) * 2006-10-04 2008-08-07 Universtiy Of South Florida Akt sensitization of cancer cells
WO2008077062A2 (en) * 2006-12-19 2008-06-26 Board Of Regents, The University Of Texas System Suppression of stat3 reactivation after src kinase inhibition to treat cancer
JP4077863B1 (ja) 2007-05-31 2008-04-23 タヒボジャパン株式会社 抗癌活性を有する光学活性２−（１−ヒドロキシエチル）−５−ヒドロキシナフト［２，３−ｂ］フラン−４，９−ジオンの製法
WO2009036099A1 (en) 2007-09-10 2009-03-19 Boston Biomedical, Inc. A novel group of stat3 pathway inhibitors and cancer stem cell pathway inhibitors
US20100298402A1 (en) 2007-11-06 2010-11-25 Orchid Research Laboratories Limited Stilbene derivatives as pstat3/il-6 inhibitors
BR122021025776B1 (pt) 2010-03-19 2022-12-27 Boston Biomedical, Inc. Composição compreendendo compostos de naftofurano e uso da mesma para tratar câncer
AU2015218436B9 (en) 2010-03-19 2017-03-09 Boston Biomedical, Inc. Novel Methods For Targeting Cancer Stem Cells
CN107721958A (zh) 2010-03-19 2018-02-23 北京强新生物科技有限公司 靶向癌症干细胞的新的化合物和组合物
RU2591823C2 (ru) 2010-03-19 2016-07-20 Бостон Байомедикал, Инк. Новые способы направленного воздействия на раковые стволовые клетки
CN103402993A (zh) 2011-03-04 2013-11-20 舟山海中洲新生药业有限公司 用于疾病治疗的4，9-二羟基-萘并[2,3-b] 呋喃新型酯
US8977803B2 (en) 2011-11-21 2015-03-10 Western Digital Technologies, Inc. Disk drive data caching using a multi-tiered memory
WO2013166618A1 (en) 2012-05-08 2013-11-14 Zhoushan Haizhongzhou Xinsheng Pharmaceuticals Co., Ltd. PRODRUGS OF 4,9-DIHYDROXY-NAPHTHO[2,3-b]FURANS FOR CIRCUMVENTING CANCER MULTIDRUG RESISTANCE
SG11201508358RA (en) 2013-04-09 2015-11-27 Boston Biomedical Inc 2-acetylnaphtho[2,3-b]furan -4,9-dione for use on treating cancer
MX2017013358A (es) 2015-04-17 2018-08-01 Boston Biomedical Inc Métodos para tratar el cáncer.
EP3283071A1 (en) 2015-04-17 2018-02-21 Boston Biomedical, Inc. Methods for treating cancer
EA201792287A1 (ru) 2015-04-17 2018-03-30 Бостон Биомедикал, Инк. Способы лечения рака
US20180250261A1 (en) 2015-04-27 2018-09-06 Boston Biomedical, Inc. Method for treating cancer with a stat3 pathway inhibitor and kinase inhibitor
MX2017015618A (es) 2015-06-03 2018-08-15 Boston Biomedical Inc Composiciones que comprenden un inhibidor de la autorrenovación y diferenciación de células madre cancerosas y un agente inmunoterapéutico para su uso en el tratamiento del cáncer.
CN109069469A (zh) 2016-01-20 2018-12-21 北京强新生物科技有限公司 治疗癌症的方法
JP2020520923A (ja) 2017-05-17 2020-07-16 ボストン バイオメディカル， インコーポレイテッド がんを処置するための方法

Also Published As

Publication number Publication date
US9834532B2 (en) 2017-12-05
ES2584904T3 (es) 2016-09-30
EP2190429B1 (en) 2016-04-20
CN101854937B (zh) 2013-03-27
HK1148943A1 (en) 2011-09-23
JP6358659B2 (ja) 2018-07-18
CN104586832A (zh) 2015-05-06
CA2911990C (en) 2018-03-20
CA2736563A1 (en) 2009-03-19
CN105963289B (zh) 2021-02-26
HRP20160430T1 (hr) 2016-05-20
CA2736564A1 (en) 2009-03-19
JP2018076349A (ja) 2018-05-17
CA2736532A1 (en) 2009-03-19
CN101854802A (zh) 2010-10-06
HUE029111T2 (hu) 2017-02-28
JP2010539095A (ja) 2010-12-16
JP2010539098A (ja) 2010-12-16
JP2019073560A (ja) 2019-05-16
US20170197932A1 (en) 2017-07-13
EP3050566A2 (en) 2016-08-03
EP2200431A1 (en) 2010-06-30
CN101854802B (zh) 2014-12-03
CN103288787A (zh) 2013-09-11
HK1148906A1 (en) 2011-09-23
JP5938072B2 (ja) 2016-06-22
JP2015034179A (ja) 2015-02-19
PT2194987T (pt) 2016-08-05
EP2200431A4 (en) 2011-12-21
US20120252763A1 (en) 2012-10-04
EP2194987B1 (en) 2016-05-18
US20180030022A1 (en) 2018-02-01
DK3050566T3 (en) 2019-03-11
US20100310503A1 (en) 2010-12-09
PL3067054T3 (pl) 2021-10-04
CN101854930A (zh) 2010-10-06
JP6346628B2 (ja) 2018-06-20
ES2569215T3 (es) 2016-05-09
US20110112180A1 (en) 2011-05-12
JP2015038151A (ja) 2015-02-26
WO2009036099A1 (en) 2009-03-19
US20180030021A1 (en) 2018-02-01
CY1117604T1 (el) 2017-04-26
US9745278B2 (en) 2017-08-29
JP5701603B2 (ja) 2015-04-15
CN104586832B (zh) 2018-02-16
HRP20160949T1 (hr) 2016-10-07
EP2200431B1 (en) 2016-07-20
CY1117833T1 (el) 2017-05-17
US20150018410A1 (en) 2015-01-15
PL2190429T3 (pl) 2016-09-30
JP2010539097A (ja) 2010-12-16
US10377731B2 (en) 2019-08-13
CN101854930B (zh) 2016-05-04
EP2190429A1 (en) 2010-06-02
HK1148942A1 (zh) 2011-09-23
EP3050566A3 (en) 2016-11-30
CN103288787B (zh) 2016-08-03
SI2200431T1 (sl) 2016-10-28
SI2194987T1 (sl) 2016-10-28
US10851075B2 (en) 2020-12-01
DK2190429T3 (en) 2016-05-30
JP5925849B2 (ja) 2016-05-25
CA2911990A1 (en) 2009-03-19
JP2016034976A (ja) 2016-03-17
CA2736563C (en) 2016-01-26
WO2009036101A1 (en) 2009-03-19
EP3050566B1 (en) 2018-11-28
US8877803B2 (en) 2014-11-04
JP2020143135A (ja) 2020-09-10
EP3067054B1 (en) 2020-12-30
EP3067054A1 (en) 2016-09-14
ES2583010T3 (es) 2016-09-16
CN105963289A (zh) 2016-09-28
HRP20160625T1 (hr) 2016-08-12
JP5688840B2 (ja) 2015-03-25
US20210115006A1 (en) 2021-04-22
US9732055B2 (en) 2017-08-15
WO2009036059A3 (en) 2009-07-02
US20210024482A1 (en) 2021-01-28
JP2018131464A (ja) 2018-08-23
JP2014231522A (ja) 2014-12-11
US20190263768A1 (en) 2019-08-29
CN101854937A (zh) 2010-10-06
JP6347795B2 (ja) 2018-06-27
PL2200431T3 (pl) 2017-01-31
US20200039948A1 (en) 2020-02-06
JP5872160B2 (ja) 2016-03-01
EP2194987A2 (en) 2010-06-16
JP2014221843A (ja) 2014-11-27
EP3058941B1 (en) 2019-05-22
DK2200431T3 (en) 2016-08-15
HUE027657T2 (hu) 2016-11-28
JP6106149B2 (ja) 2017-03-29
SI2190429T1 (sl) 2016-10-28
PT2200431T (pt) 2016-08-03
JP2020117547A (ja) 2020-08-06
CA2736532C (en) 2018-03-20
US20190135773A1 (en) 2019-05-09
WO2009036059A2 (en) 2009-03-19
EP3058941A1 (en) 2016-08-24
JP2016147906A (ja) 2016-08-18
EP2190429A4 (en) 2011-12-14
PL2194987T3 (pl) 2017-01-31
JP2016094465A (ja) 2016-05-26
DK2194987T3 (en) 2016-08-15
EP2194987A4 (en) 2011-11-30
CY1118476T1 (el) 2017-07-12
JP2016065101A (ja) 2016-04-28

Similar Documents

Publication Publication Date Title
US20210024482A1 (en) Novel Group of STAT3 Pathway Inhibitors and Cancer Stem Cell Pathway Inhibitors
JP2010539097A5 (hu)
ES2713455T3 (es) Un grupo novedoso de inhibidores de la ruta STAT3 e inhibidores de la ruta de células madre de cáncer